The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. I...
Gespeichert in:
Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-09, Vol.15 (9), p.e45602-e45602 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e45602 |
---|---|
container_issue | 9 |
container_start_page | e45602 |
container_title | Curēus (Palo Alto, CA) |
container_volume | 15 |
creator | Jamous, Yahya F Alhomoud, Dalal A |
description | The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently.Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. |
doi_str_mv | 10.7759/cureus.45602 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10588549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2884557484</sourcerecordid><originalsourceid>FETCH-LOGICAL-c277t-9239e8d5aec828b2566068d9b85fb73bbff5df43ec4e30ad83f5eb23c28ec7153</originalsourceid><addsrcrecordid>eNpdkU1Lw0AQhoMoWGpv_oAFLx5M3exHdnPSUuoHFIW29rpsNrNtSpKt2aTQf29qi6inGWYeXmZ4guA6wkMheHJv2hpaP2Q8xuQs6JEolqGMJDv_1V8GA-83GOMIC4IF7gWPizWgubbQ7JGuMjSxFkyT76AC75GzqJy9jdBSG5N3EzRa6bzyDZqPZvNw7JYhuQourC48DE61H3w8TRbjl3D6_vw6Hk1DQ4RowoTQBGTGNRhJZEp4HONYZkkquU0FTVNreWYZBcOAYp1JajmkhBoiwYiI037wcMzdtmkJmYGqqXWhtnVe6nqvnM7V302Vr9XK7VSEuZScJV3C7Smhdp8t-EaVuTdQFLoC13pFpMSSMBGzDr35h25cW1fdfweKcS6YPFB3R8rUzvsa7M81EVYHJ-roRH07oV94aH9B</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884557484</pqid></control><display><type>article</type><title>The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Jamous, Yahya F ; Alhomoud, Dalal A</creator><creatorcontrib>Jamous, Yahya F ; Alhomoud, Dalal A</creatorcontrib><description>The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently.Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.45602</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Allergy/Immunology ; Clinical trials ; COVID-19 vaccines ; Disease transmission ; Epidemiology/Public Health ; Good Manufacturing Practice ; Immune system ; Infectious Disease ; International organizations ; Lipids ; mRNA vaccines ; Pandemics ; Peptides ; Polyethylene glycol ; Proteins ; RNA polymerase ; Severe acute respiratory syndrome coronavirus 2 ; Stem cells</subject><ispartof>Curēus (Palo Alto, CA), 2023-09, Vol.15 (9), p.e45602-e45602</ispartof><rights>Copyright © 2023, Jamous et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Jamous et al. 2023 Jamous et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c277t-9239e8d5aec828b2566068d9b85fb73bbff5df43ec4e30ad83f5eb23c28ec7153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588549/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids></links><search><creatorcontrib>Jamous, Yahya F</creatorcontrib><creatorcontrib>Alhomoud, Dalal A</creatorcontrib><title>The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2</title><title>Curēus (Palo Alto, CA)</title><description>The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently.Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.</description><subject>Allergy/Immunology</subject><subject>Clinical trials</subject><subject>COVID-19 vaccines</subject><subject>Disease transmission</subject><subject>Epidemiology/Public Health</subject><subject>Good Manufacturing Practice</subject><subject>Immune system</subject><subject>Infectious Disease</subject><subject>International organizations</subject><subject>Lipids</subject><subject>mRNA vaccines</subject><subject>Pandemics</subject><subject>Peptides</subject><subject>Polyethylene glycol</subject><subject>Proteins</subject><subject>RNA polymerase</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Stem cells</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU1Lw0AQhoMoWGpv_oAFLx5M3exHdnPSUuoHFIW29rpsNrNtSpKt2aTQf29qi6inGWYeXmZ4guA6wkMheHJv2hpaP2Q8xuQs6JEolqGMJDv_1V8GA-83GOMIC4IF7gWPizWgubbQ7JGuMjSxFkyT76AC75GzqJy9jdBSG5N3EzRa6bzyDZqPZvNw7JYhuQourC48DE61H3w8TRbjl3D6_vw6Hk1DQ4RowoTQBGTGNRhJZEp4HONYZkkquU0FTVNreWYZBcOAYp1JajmkhBoiwYiI037wcMzdtmkJmYGqqXWhtnVe6nqvnM7V302Vr9XK7VSEuZScJV3C7Smhdp8t-EaVuTdQFLoC13pFpMSSMBGzDr35h25cW1fdfweKcS6YPFB3R8rUzvsa7M81EVYHJ-roRH07oV94aH9B</recordid><startdate>20230920</startdate><enddate>20230920</enddate><creator>Jamous, Yahya F</creator><creator>Alhomoud, Dalal A</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230920</creationdate><title>The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2</title><author>Jamous, Yahya F ; Alhomoud, Dalal A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c277t-9239e8d5aec828b2566068d9b85fb73bbff5df43ec4e30ad83f5eb23c28ec7153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergy/Immunology</topic><topic>Clinical trials</topic><topic>COVID-19 vaccines</topic><topic>Disease transmission</topic><topic>Epidemiology/Public Health</topic><topic>Good Manufacturing Practice</topic><topic>Immune system</topic><topic>Infectious Disease</topic><topic>International organizations</topic><topic>Lipids</topic><topic>mRNA vaccines</topic><topic>Pandemics</topic><topic>Peptides</topic><topic>Polyethylene glycol</topic><topic>Proteins</topic><topic>RNA polymerase</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jamous, Yahya F</creatorcontrib><creatorcontrib>Alhomoud, Dalal A</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jamous, Yahya F</au><au>Alhomoud, Dalal A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2023-09-20</date><risdate>2023</risdate><volume>15</volume><issue>9</issue><spage>e45602</spage><epage>e45602</epage><pages>e45602-e45602</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently.Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.The clinical data reviewed in this article demonstrate that the currently authorized Moderna and Pfizer-BioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><doi>10.7759/cureus.45602</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-8184 |
ispartof | Curēus (Palo Alto, CA), 2023-09, Vol.15 (9), p.e45602-e45602 |
issn | 2168-8184 2168-8184 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10588549 |
source | PubMed Central Open Access; PubMed Central |
subjects | Allergy/Immunology Clinical trials COVID-19 vaccines Disease transmission Epidemiology/Public Health Good Manufacturing Practice Immune system Infectious Disease International organizations Lipids mRNA vaccines Pandemics Peptides Polyethylene glycol Proteins RNA polymerase Severe acute respiratory syndrome coronavirus 2 Stem cells |
title | The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T06%3A39%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Safety%20and%20Effectiveness%20of%20mRNA%20Vaccines%20Against%20SARS-CoV-2&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Jamous,%20Yahya%20F&rft.date=2023-09-20&rft.volume=15&rft.issue=9&rft.spage=e45602&rft.epage=e45602&rft.pages=e45602-e45602&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.45602&rft_dat=%3Cproquest_pubme%3E2884557484%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2884557484&rft_id=info:pmid/&rfr_iscdi=true |